ArticleFrontiers in endocrinology2026
Proteins at the intersection of circadian rhythms and metabolic dysfunction-associated steatotic liver disease: an 18-protein panel as a novel predictive biomarker set.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Circadian control of immune homeostasis in cardiovascular health and disease.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disruption of circadian rhythmicity is highly prevalent in modern society and contributes to the epidemic of metabolic disorders. However, the relationship between circadian rhythm disorder and Metabolic Dysfunction-Associated Steatotic Liver (MASLD) remained poorly elucidated. Relative amplitude (RA), a metric quantifying the degree of disruption in rest-activity circadian rhythms, was calculated based on accelerometry data from UK Biobank. Basic characteristic analysis and multivariable logistic regression was used to analyze the association between RA and MASLD. Mediation analysis, functional enrichment analysis (Kyoto Encyclopedia of Genes and Genomes, KEGG) and Protein-Protein Interaction (PPI) network analysis and multiple machine learning algorithms, including Random Forest, XGBoost, logistic regression, and Support Vector Machine (SVM), were employed to identify potential protein biomarkers and construct a predictive model for RA-related MASLD risk assessment. Among 81,430 UK Biobank participants with valid accelerometry, RA was lower in individuals with MASLD versus those without (P < 0.001). Lower RA was associated to higher prevalence of MASLD (crude OR = 2.61; 95% CI [2.42, 2.81]; P < 0.001), and the association remained significant in a fully adjusted model (adjusted OR = 1.15; 95% CI [1.02,1.31]; P = 0.026), demonstrating RA as a factor independently associated with MASLD. Furthermore, 18 candidate proteins were identified as potential biomarkers for predicting RA-related MASLD. The 18-protein model demonstrated excellent predictive performance across multiple machine learning methods, with high Area Under the Curve (AUC) values in Receiver Operating Characteristic (ROC) analysis: Random Forest (AUC = 0.944), XGBoost (AUC = 0.946), Logistic Regression (AUC = 0.946), and SVM (AUC = 0.947). The model also exhibited superior discriminatory ability in predictive probability distribution, indicating strong predictive potential. Additionally, an online predictive tool based on this model has been contributed. Lower RA is independently associated with MASLD. We highlight 18 overlapping plasma proteins linked to both RA and MASLD as potential biomarkers for predicting RA-associated MASLD and as candidate therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.